Rapport Therapeutics closes $172.5 million convertible senior notes offering
RAPP•Rapport Therapeutics closed a $172.5 million offering of 2.25% convertible senior notes due 2032, bringing combined net proceeds from the notes, equity offerings and concurrent private placement to approximately $410.7 million.
